bioAffinity Technologies, Inc. announced in October 2024 that its CyPath® Lung test was added to the U.S. Federal Supply Schedule. This contract provides the Veterans Health Administration (VHA) and the Military Health System with streamlined access to the noninvasive diagnostic test for early-stage lung cancer.
The VHA, a part of the U.S. Department of Veterans Affairs, serves 9.1 million Veterans annually across 1,380 healthcare facilities. Approximately 8,000 Veterans are diagnosed and treated for lung cancer each year, making this a substantial new market for CyPath® Lung.
An economic impact study indicated that integrating CyPath® Lung into the current standard of care could save hundreds of millions of dollars annually in healthcare costs. These savings would result from reducing follow-up diagnostic assessments, expensive procedures, and procedure-related complications, highlighting the test's clinical and economic value for federal health services patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.